Exxonmobil Investment Management Inc. TX Has $5.07 Million Stake in Illumina, Inc. (ILMN)

Exxonmobil Investment Management Inc. TX reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 23,215 shares of the life sciences company’s stock after selling 3,447 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Illumina were worth $5,072,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Private Asset Management Inc. boosted its holdings in Illumina by 2.2% during the fourth quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after purchasing an additional 240 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Illumina by 41.2% during the third quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock worth $57,859,000 after purchasing an additional 84,690 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in Illumina by 7.1% during the third quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock worth $1,497,000 after purchasing an additional 500 shares during the last quarter. IFM Investors Pty Ltd purchased a new position in Illumina during the third quarter worth about $804,000. Finally, DF Dent & Co. Inc. boosted its holdings in Illumina by 4.0% during the third quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after purchasing an additional 18,741 shares during the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $242.59 on Thursday. Illumina, Inc. has a 12-month low of $156.50 and a 12-month high of $245.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The stock has a market cap of $35,420.00, a P/E ratio of 45.77, a PEG ratio of 3.13 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the previous year, the firm posted $0.97 earnings per share. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. sell-side analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.

Several research firms recently weighed in on ILMN. Canaccord Genuity restated a “buy” rating and set a $230.00 price target (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Goldman Sachs Group restated a “neutral” rating and set a $200.00 price target on shares of Illumina in a report on Tuesday, September 26th. Wells Fargo & Co upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $214.38.

In related news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the sale, the director now owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $207.88, for a total transaction of $334,478.92. Following the sale, the senior vice president now directly owns 7,217 shares in the company, valued at approximately $1,500,269.96. The disclosure for this sale can be found here. In the last three months, insiders sold 137,671 shares of company stock worth $29,485,768. Insiders own 0.89% of the company’s stock.

WARNING: This piece of content was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/11/exxonmobil-investment-management-inc-tx-has-5-07-million-stake-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply